drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous genetically engineered T cells expressing a chimeric antigen receptor targeting CD19, using CD3ζ signaling with 4-1BB or CD28 costimulation to mediate cytokine release and cytotoxic killing of CD19+ B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a CD19-specific chimeric antigen receptor; binding to CD19 triggers CD3ζ signaling with 4-1BB or CD28 costimulation, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated killing of CD19+ B-cell malignancies.
drug_name
Anti-CD19 CAR T-cell therapy
nct_id_drug_ref
NCT05887167